West Virginia University Logo

Disease Site: Pediatric Cancer

17 protocol(s) meet the specified criteria

  • COG-AALL0932Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
  • COG-AALL1131A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
  • COG-AALL1231AALL1231 - A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
  • COG-AALL1331Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND #117467, NSC #765986) i First Relapse of childhood B-Lymphoblastic Leukemia
  • COG-ACNS02B3A COG Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
  • COG-ACNS0831ACNS0831- Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
  • COG-AEWS1031COG-AEWS1031 - A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
  • COG-AEWS1221Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
  • COG-AHEP0731COG AHEP0731 - Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment
  • COG-AHOD1331AHOD1331 - A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
  • COG-ANBL00B1Neuroblastoma Biology Studies
  • COG-ANBL1232COG-ANBL1232 - Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma - A Group Wide Historically Controlled Phase III Study
  • COG-AOST06B1A COG Protocol for Collecting and Banking Osteosarcoma Specimens
  • COG-AOST1321Phase 2 Study of Denosumab, a RANK Liggand Antibody, for Recurrent or Refractory Osteosarcoma
  • COG-AOST1421A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
  • COG-APEC14B1APEC14B1 - Project: EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study.
  • COG-ARST1321COG-ARST1321 Pazopanib Neoadjuvant Trial in Non-Rhadomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)